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Abstract
The polyglutamic acid/peptoid 1 (QM56) nanoconjugate inhibits apoptosis by interfering with Apaf-1 binding to
procaspase-9. We now describe anti-inflammatory properties of QM56 in mouse kidney and renal cell models.
In cultured murine tubular cells, QM56 inhibited the inflammatory response to Tweak, a non-apoptotic stimulus. Tweak
induced MCP-1 and Rantes synthesis through JAK2 kinase and NF-kB activation. Similar to JAK2 kinase inhibitors, QM56
inhibited Tweak-induced NF-kB transcriptional activity and chemokine expression, despite failing to inhibit NF-kB-p65
nuclear translocation and NF-kB DNA binding. QM56 prevented JAK2 activation and NF-kB-p65(Ser536) phosphorylation.
The anti-inflammatory effect and JAK2 inhibition by QM56 were observed in Apaf-12/2 cells.
In murine acute kidney injury, QM56 decreased tubular cell apoptosis and kidney inflammation as measured by down-
modulations of MCP-1 and Rantes mRNA expression, immune cell infiltration and activation of the JAK2-dependent
inflammatory pathway. In conclusion, QM56 has an anti-inflammatory activity which is independent from its role as
inhibitor of Apaf-1 and apoptosis and may have potential therapeutic relevance.
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Introduction
Acute kidney injury (AKI) and progressive loss of renal function
in chronic kidney disease (CKD) are associated with interstitial
inflammation and loss of tubular cells. Infiltration by leucocytes
depends on the local expression of inflammatory cytokines released
by renal cells. Renal tubular cells compose most of the mass of the
functioning kidney and they are thought to be a central cell type in
renal inflammation [1]. Tubular cells release an array of cytokines
and chemokines in response to various immune and non-immune
factors, contributing to attraction of inflammatory cells to the
kidney [2]. Chemokines and their receptors contribute to tissue
injury in animal models of inflammatory kidney disease and their
therapeutic targeting decreases inflammation and tissue injury
during renal disease [3]. NF-kB is a key promoter of inflammation
in the kidney that integrates intracellular signals derived from
many inflammatory stimuli and drives the expression of cytokines
and chemokines. Pharmacological targeting of NF-kB has also
been proposed as a therapy to reduce kidney damage [4]. Similar
to nephrotoxins such as cyclosporine A (CsA), inflammatory
cytokines may induce tubular cell injury and death [5,6].
Cytokines belonging to the TNF superfamily may also induce an
inflammatory response [7]. Thus, tissue injury leads to inflamma-
tion and inflammation may promote tissue injury. In this regard,
drugs that prevent tissue injury, by protecting from apoptotic cell
death, and, additionally, limit the inflammatory response, may be
especially useful in kidney disease.
Apoptosis is an active process of cell death that regulates cell
number [8]. Apoptosis has potential therapeutic relevance, since it
is regulated by the activation of intracellular lethal molecules in
response to the cell environment. Caspases are intracellular
cysteine proteases that behave as activators and effectors of
apoptosis, and play a central role in the process [8]. Caspases may
be activated through a death receptor-dependent and a mito-
chondrial pathway. Death receptor-dependent apoptosis is often
amplified by the mitochondrial pathway. Activation of such
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pathway leads to the release of proapoptotic molecules, such as
cytochrome c, from mitochondria into the cytoplasm. In the
presence of dATP, cytochrome c induces the formation of the
Apaf-1 (apoptotic protease activating factor 1)-containing macro-
molecular complex called the apoptosome. This complex binds to
and activates caspase-9. Mature caspase-9 activates effector
caspases, leading to apoptotic cell death [9].
Recent reports have proposed the apoptosome as an interesting
target for the development of apoptosis inhibitors [10,11].
Polyglutamic acid-based nanoconjugates (PGA-peptoids) are well
suited for in vivo applications [11]. The polymeric nanoconjugate
PGA-peptoid QM56 is a first generation Apaf-1 inhibitor that
prevents apoptosome formation and hence caspase activation and
apoptotic cell death. Binding of procaspase-9 to Apaf-1 is
mediated by caspase recruitment domain (CARD)/CARD inter-
actions [12]. The compound action may be mediated by direct
interaction with the CARD motif of Apaf-1 precluding the
recruitment of procaspase-9 by Apaf-1 [11]. It has been previously
demonstrated that QM56 prevents apoptosis of tumor cells
induced by antitumor drugs and also protects cultured cardiomy-
ocytes from hypoxia-induced death [13]. Moreover, QM56
protects mesothelial cells from cytokine- and toxin-induced injury
(cell death and remesothelization prevention) in culture and in vivo
[14]. In this work, we were addressed potential beneficial effects of
QM56 on the kidney. While researching the possible implications
of inhibition of renal cell apoptosis by QM56 we observed a potent
anti-inflammatory effect. Here we describe this new anti-inflam-
matory effect of QM56 independent of its anti-apoptotic action
that may contribute to the protection from experimental AKI
afforded by the compound in vivo.
Materials and Methods
Ethics Statements
Studies were conducted in accord with the NIH Guide for the
Care and Use of Laboratory Animals (NIH Publication Nu 85-23,
revised 1996) and was approved by the institution’s animal subject
review committee. Emphasis was made in the humane care of the
animals.
Cells and reagents
MCT cells are a cultured line of murine proximal tubular
epithelial cells originally obtained from Eric Neilson (Vanderbildt
University, Nashville, TN) that have been extensively character-
ized [15]. Homozygous embryonic fibroblasts from Apaf-12/2
mice (MEF-Apaf-12/2) and wild-type controls (MEF-Apaf-1+/+)
[16] were generously donated by Prof Francesco Cecconi (Biology
Department, University of Rome ‘‘Tor Vergata’’, Rome, Italy).
Both cell lines were grown as described in Materials and Methods
S1. Unless otherwise specified, the concentration of Tweak
(Millipore, Temecula, CA) was 100 ng/ml, murine TNFa
(Peprotech, London, UK) 30 ng/ml and human interferon-c
(INFc) (Peprotech) 30 U/ml. CsA (10 mg/ml stock solution in
ethanol) (Calbiochem, La Jolla, CA) was added at a final
concentration of 10 mg/ml. Based on previous experience and
set-up experiments, cell death was assessed at 24 h (Tweak/
TNFa/IFNc) or 48 h (CsA) [5,6]. The QM56 initial dose range
was chosen based on published dose-response curves and dose-
response studies [13,14]. Additional dose-response studies were
performed in MCT cells exposed to CsA and the concentration
chosen for the studies was 20 mmol/L drug-equivalents. The JAK2
inhibitors AG490 and JAK2 Inhibitor II (50 mmol/L, Calbio-
chem) were used according at concentrations previously observed
to offer complete protection against apoptotic challenge [17].
Additionally Western blot experiments confirmed inhibition of
JAK2 phosphorylation. Parthenolide (Sigma-Aldrich, St Louis,
MO) 10 mmol/L inhibits NF-kB in MCT cells without decreasing
cell viability [2]. Lipopolysaccharide from E.Coli was purchased
from Sigma-Aldrich.
Synthesis of PGA-peptoid 1 conjugate QM56
The antiapoptotic polymeric nanomedicine, PGA-peptoid
QM56, is the result of the conjugation of peptoid 1 to poly-L-
glutamic acid (PGA) according to a standardized procedure [10]
(See Materials and Methods S1). Full structural and biophysical
characterization of this nanoconjugate was previously performed
[10].
Apoptosis
In renal tubular cells, apoptosis was characterized by functional
and morphologic criteria [6] (See Materials and Methods S1).
Cells were permeabilized and propidium iodide stained and the
cell cycle analyzed by flow cytometry. Alternatively, apoptotic
nuclei were observed using DAPI (Vector Laboratories, Inc.,
Burlingame, CA) staining. In renal tissue, apoptotic cell death was
assessed by enzymatic in situ labeling of DNA strand breaks using
terminal deoxynucleotidyl-transferase-mediated dUTP nick-end
labeling (TUNEL) (In Situ Cell Death Detection Kit; Promega,
Madison, WI).
Quantitative reverse transcription-polymerase chain
reaction
One mg RNA isolated by Trizol (Life Technologies, Carlsbad,
CA) was reverse transcribed with High Capacity cDNA Archive
Kit and real-time PCR was performed on a ABI Prism 7500 PCR
system (Applied Biosystems, Foster City, CA) using the DeltaDelta
Ct method. Expression levels are given as ratios to GAPDH. Pre-
developed primer and probe assays were from Applied Biosystems.
ELISA
Cells were stimulated with 100 ng/mL Tweak and murine
MCP-1 in the supernatants was determined by ELISA (BD
Pharmingen, NJ) according to manufacturer’s instructions.
Immunostaining
Cells plated onto LabtekTM slides were fixed in 4% parafor-
maldehyde and permeabilized in 0.2% Triton X-100/PBS,
washed in PBS and incubated with rabbit polyclonal anti-RelA
(1:75) (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit
policlonal anti-phospho STAT3-(Ser727)(1:100) (Cell Signaling
Technology, Danvers, MA) or rabbit monoclonal antibody anti-
phospho-NF-kB p65 (Ser536)(1:100) (Cell Signaling Technology,
Danvers, MA) followed by FITC secondary antibody (1:200,
Sigma-Aldrich, Spain). Nuclei were counterstained with propi-
dium iodide.
Electrophoretic mobility shift assay (EMSA)
Cells were resuspended and homogenized in extraction buffer
(see Materials and Methods S1) and EMSA was carried out as
previously described [2].
NF-kB Luciferase Reporter Assay
MCT cells were plated at a density of 86104 cells in six-well
plates 24 h before transfection with FuGENE 6 (Roche, India-
napolis, IN), according to the manufacturer’s intructions. pNF-kB-
Luc (Stratagene, La Jolla, CA) and pRLTK vectors, which
contains the luciferase gene Renilla (Promega), were used in a ratio
Nanoconjugate Prevents Inflammation in Renal Cells
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e51992
of 10:1. The medium was replaced with RPMI without serum 4 h
after transfection and cells were treated with the stimuli. Luciferase
activity was determined by a luciferase assay system (Promega) and
a luminometer (Berthold, Nashua, NH) and normalized to Renilla
activity to control for differences in transfection efficiency.
Western blot
Standard procedures were applied (See Materials and Methods
S1) [5]. The following primary antibodies were used: anti p65 and
anti-JAK2 (Santa Cruz Biotechnology), anti phospho JAK2
(pYpY1007 1008) (Invitrogen, Camarillo, CA) and anti-phospho
Stat 3 (Ser727) and anti-Stat 3 (Cell Signaling Technology) rabbit
polyclonal antibodies; anti-phospho-NF-kB p65 (Ser536) and anti-
phospho IkBa (Cell Signaling Technology) rabbit monoclonal
antibody; anti-Apaf-1 (BD Pharmingen) and anti-a-Tubulin
(Sigma-Aldrich) mouse monoclonal antibody; anti-GAPDH (Che-
micon International, Temecula, CA) mouse polyclonal antibody.
Animal model
Folic acid nephropathy is a classical model of AKI [18–20];
C57/BL6 mice from 12- to 14-week-old (IFFA-CREDO,
Barcelona, Spain) received a single intra-peritoneal injection of
folic acid (Sigma-Aldrich) 250 mg/kg in 0.3 M sodium bicarbon-
ate or vehicle and mice were killed 24 h later. A single dose of
QM56 (100 mg/Kg) was intravenously administered 6 hour
before folic acid. Groups (n = 8–10) were as follows: a) Healthy
control (folic acid vehicle), b) AKI (Folic acid plus QM56 vehicle),
c) AKI plus QM56. Blood was drawn for urea and creatinine
assessment and the kidneys were perfused in situ with cold saline
before removal. One kidney was snap-frozen in liquid nitrogen for
protein and RNA studies and the other fixed and paraffin
embedded.
Immunohistochemistry
Paraffin-embedded sections were stained using standard histol-
ogy procedures. Immunostaining was carried out in 3 mm thick
tissue sections that were deparafinized and antigen retrieved using
the PT Link system (Dako Diagnostics, Barcelona, Spain) with
Sodium Citrate Buffer (10 mM) adjusted to pH 6 or pH 9
depending on the immunohystochemical marker. Inmmunohisto-
chemical staining was performed using the Dako Autostainer
(Dako Diagnostics). Briefly: endogenous peroxidase was blocked
and then sections were incubated for 20–30 min at room
temperature with primary antibody: rabbit polyclonal anti active
caspase 3 (Promega), and monoclonal mouse anti CD68 and
rabbit polyclonal anti-CD3 (Dako Diagnostics) ready to use. After
washing, slides were treated with the EnVisionTM DuoFLEX
Doublestain System using 3,39-diaminobenzidine as cromogen.
Sections were counterstained with Carazzi’s hematoxylin. The
total number of caspase 3 stained tubuli was counted in 10
randomly chosen fields (2006) and the result expressed as the
Mean6SD of positive tubuli per field. The total number of CD68
and CD3 positive stained cells was quantified in at least 5
randomly chosen fields (2006) using Image-Pro Plus software.
Data are expressed as positive stained area vs. total analyzed area.
Samples from each animal were examined in a blind manner.
Statistics
Statistical analysis was performed using SPSS 11.0 (SPSS,
Chicago, IL). Results are expressed as mean 6 SD. Significance at
the p,0.05 level was assessed by non-parametric Mann-Whitney
test for two groups of data and Kruskal-Wallis for three of more
groups.
Results
QM56 inhibits apoptosis and expression of chemokines
induced by different cell death stimuli in renal tubular
epithelial cells
Tubular cell apoptosis and inflammation contribute to the
pathogenesis of AKI and CKD. Lethal cytokines, in particular the
association Tweak/TNFa/IFNc, and the exogenous nephrotoxin
CsA are well-characterized tubular cell death inducers. Tweak/
TNFa/IFNc activates the intrinsic apoptotic pathway following
caspase 8 activation, while CsA directly targets the mitochondria
[5,6]. As expected from its known action in other cell systems,
QM56 protected cultured renal tubular cells from apoptosis
induced by the lethal cytokine cocktail Tweak/TNFa/IFNc or by
CsA (Figure 1, A and B). Interestingly, both apoptotic stimuli also
induced the rapid expression of MCP-1 and Rantes mRNA and
this was prevented by QM56 (Figure 1, C and D). The effect of
QM56 on chemokine expression was rather unexpected and
encouraged us to investigate the possible anti-inflammatory
properties of QM56 and their relationship with protection from
apoptosis. Prevention of chemokine expression preceded in time
the protection from apoptosis, suggesting that both actions of
QM56 might be independent from each other. Thus, for further
experiments we chose Tweak as a stimulus, since in this cell system
Tweak promotes inflammation, but not apoptosis, and thus we
could dissociate effects related to apoptosis from those related to
inflammation.
QM56 inhibits expression of chemokines induced by
Tweak, a non-lethal stimulus
Tweak is a mediator of tubulointerstitial inflammation in AKI
that does not promote apoptosis in non-stressed renal tubular cells
[2,6]. We confirmed the lack of lethality of Tweak in the present
experiments (Figure 2.A). In this system, in the absence of cell
death, QM56 prevented Tweak-induced upregulation of MCP-1
and Rantes mRNA expression in a dose-dependent manner
(Figure 2B). In most experiments cells were stimulated by Tweak
for 3 hours. However, time-course experiments demonstrated that
QM56 prevented an increase in chemokine mRNA expression
from as early as 30 minutes following Tweak stimulation
(Figure 2C). QM56 also reduced chemokine secretion to the
culture supernatant in response to Tweak, as exemplified by MCP-
1 (Figure 2D). These results indicate that the anti-inflammatory
effect of QM56 is observed in an experimental system where
inflammation was triggered by a stimulus that did not promote
apoptosis.
QM56 inhibits inflammation in Apaf-1 null cells
In order to test whether the anti-inflammatory action of QM56
was dependent on its ability to inhibit Apaf-1, we tested Apaf-1
knock-out murine embryonic fibroblasts (MEF-Apaf-12/2). It has
been previously described that these cells are protected from pro-
apoptotic stimuli [16]. Gene and protein expression analysis
confirmed lack of Apaf-1 in these cells (Figure S1, A and B).
Tweak promoted the expression of MCP-1 and Rantes mRNA in
MEF-Apaf-12/2 and this effect was prevented by QM56
(Figure 2E). This result suggests that inhibition of the inflamma-
tory response by QM56 does not involve Apaf-1.
QM56 does not prevent early NF-kB activation induced
by Tweak in tubular cells
The pro-inflammatory effect of Tweak on MCP-1 and Rantes
expression is mediated by NF-kB activation and p65/relA
Nanoconjugate Prevents Inflammation in Renal Cells
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Figure 1. QM56 protects tubular cells from apoptosis and prevents the expression of CsA and cytokines-induced chemokines. A)
MCT tubular cells were cultured in the presence of 100 ng/ml Tweak, 30 ng/ml TNFa, 30 U/ml IFNc for 24 h or in the presence of 10 mg/ml CsA for
48 h. QM56 (10 mM) was added 1 h before lethal stimuli. Cell death was assessed by the DNA content of cell population stained with propidium
iodide followed by flow cytometry. The percentage of cells with sub-G1 DNA content (hypodiploid cells) is considered as apoptotic (*p,0.01 vs
Control; **p,0.01 vs Tweak/TNFa/INFc; ##p,0.05 vs CsA). B) Contrast phase microscopy and assessment of nuclear morphology in MCT cells
stained with DAPI (inset images) confirmed protection from apoptosis by QM56. Arrows indicate typical apoptotic cells with characteristic shrunk,
Nanoconjugate Prevents Inflammation in Renal Cells
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pyknotic and fragmented nuclei present among Tweak/TNFa/INFc- and CsA-treated cells but not among control cells. C) QM56 prevents the
upregulation of MCP-1 and Rantes mRNA (qRT-PCR) in MCT cells exposed to Tweak/TNFa/INFc for 3 h. (*p,0.01 vs Control, **p,0.05 and##p,0.01
vs Tweak/TNFa/INFc). D) QM56 prevents the upregulation of MCP-1 and Rantes mRNA in MCT cells exposed to CsA for 6 h (*p,0.05 vs Control,
**p,0.05 vs CsA). Results are expressed as the Mean6SD of at least five independent experiments.
doi:10.1371/journal.pone.0051992.g001
Figure 2. QM56 prevents the expression of inflammatory mediators induced by the non-lethal stimulus Tweak. A) Treatment with
100 ng/ml Tweak for 24 h does not promote apoptosis (Ap) in MCT cultured tubular cells. Apoptotic cells were measured by flow cytometry analysis
of DNA content in cells stained with propidium iodide and the cell nuclear morphology through DAPI staining followed by phase contrast
microscopy as in Fig. 1 (inseted images). B) QM56 dose-dependently prevents the upregulation of MCP-1 and Rantes. qRT-PCR in MCT cells exposed
to Tweak for 3 h. Mean6SD of three independent experiments. *p,0.05 vs Control, **p,0.05 vs Tweak. C) QM56 prevents the upregulation of MCP-
1 in MCT tubular cells in response to 100 ng/ml Tweak from very early time points. Representative experiment. D) QM56 prevents the upregulation of
MCP-1 (ELISA) in supernatants from MCT cells treated with 100 ng/ml Tweak. Mean6SD of three independent experiments.*p,0.05 vs Control,
**p,0.05 vs Tweak. E) QM56 prevents the upregulation of MCP-1 and Rantes mRNA in MEF-Apaf-12/2 cells stimulated with Tweak. (*p,0.01 vs
control,**p,0.01 vs Tweak). Mean6SD of four independent experiments.
doi:10.1371/journal.pone.0051992.g002
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translocation to the nucleus [2]. In this regard, the inhibitor of Ik-
Ba degradation parthenolide [21], prevented Tweak-induced NF-
kB p65/RelA nuclear translocation, NF-kB DNA-binding activity,
NF-kB transcriptional activity and upregulation of MCP-1 and
Rantes mRNA in tubular cells [2]. We tested whether QM56 may
inhibit some of these steps. QM56 prevented Tweak-induced
upregulation of NF-kB-dependent genes from very early time
points (Figure 2C) and repressed the overall NF-kB transcriptional
activity measured by gene reporter assay (Figure 3A). However,
neither IkBa phosphorylation events nor the consequent NF-kB
p65/relA nuclear translocation in response to Tweak in tubular
cells were observed to be inhibited (Figure 3B and 3C).
Furthermore, QM56 did not prevent nuclear NF-kB DNA-
binding in response to Tweak, as assessed by EMSA (Figure 3D).
Inhibition of JAK2 prevents Tweak-induced chemokine
mRNA expression in tubular cells and MEFs
Protein phosphorylation regulates multiple steps in signal
transduction and gene transcription. The JAK/STAT pathway
mediates renal damage and inflammation [17,22]. While studying
the role of JAK/STAT in kidney injury we observed that Tweak
induced phosphorylation of JAK2 and its downstream substrate
Stat-3 which were inhibited by AG490 in tubular cells (Figure 4A)
and chemical inhibition of JAK2 by AG490 prevented Tweak-
induced chemokine mRNA expression (Figure 4B). The JAK2
inhibitor II also prevented Tweak-induced upregulation of MCP-1
and Rantes mRNA levels (25% MCP-1 and Rantes mRNA
expression compared to 100% MCP-1 and Rantes mRNA
expression in presence of Tweak alone; p,0.01, not shown).
Similar to QM56, AG490 did not interfere with Tweak-induced
NF-kB nuclear translocation (Figure 4C), but repressed the overall
NF-kB transcriptional activity measured by gene reporter assay
(Figure 4D). Furthermore, like QM56, AG490 prevented Tweak-
induced chemokine mRNA expression in MEF-Apaf-12/2
(Figure 4E). The similarity between the effects of AG490 and
QM56 suggested that QM56 may inhibit JAK2 activity and we
tested this hypothesis.
QM56 inhibits JAK2 in tubular cells and MEFs
QM56 prevented Tweak-induced phosphorylation of JAK2 and
its downstream target STAT3 (Figure 5A) and pSTAT3 nuclear
translocation in tubular cells (Figure 5B). Tweak stimulation also
resulted in JAK2 and STAT3 phosphorylation in MEF-Apaf-12/2
which was prevented by QM56 (Figure 5C). The inhibitory action
of QM56 on JAK2 was also observed in cells treated with CsA and
Tweak/TNFa/INFc (Figure S2). These results suggest that
inhibition of JAK2 activation could contribute to the observed
anti-inflammatory effect of QM56.
QM56 interferes with activating posttranslational
modification of NF-kB
Phosphorylation of transcription factors modulates their tran-
scriptional activity [23]. Phosphorylation of Ser536 on p65 has
been related to transcriptional control of NF-kB-regulated
inflammatory genes [24,25]. Tweak time-dependently increased
p65 phosphorylation at Ser536 (Figure 6A). This was significantly
attenuated by QM56 or AG490 (Figure 6B). Moreover, Tweak-
induced phospho-p65 (Ser536) nuclear translocation was inhibited
by QM56 or AG490 (Figure 6C). Finally, to address whether NF-
kB-dependent chemokines synthesis inhibition by QM56 was
stimulus dependent, we treated tubular cells with LPS as another
representative NF-kB agonistic activity. Whereas LPS activated
JAK2/STAT3/p-p65 pathway and consequently induced chemo-
kine expression, QM56 significantly prevented or reduced LPS-
engaged signaling and resulting inflammatory events (Figure S3).
These results demonstrate that JAK2 modulates p65 Ser536
phosphorylation and suggest that QM56 may interfere with the
complete activation of NF-kB-dependent chemokine gene expres-
sion through inhibition of JAK2 and p65 (Ser536) phosphoryla-
tion.
QM56 reduces renal chemokine gene expression during
AKI
In order to assess the potential implications of the observed
action of QM56 in cultured tubular cells, QM56 was tested in an
animal model of AKI that shares features with human AKI, such
as tubular cell apoptosis and inflammation [18–20,26]. AKI was
induced by a single folic acid overdose. QM56 seemed to
ameliorate renal function of FA-treated mice as judged by lower
plasma urea and creatinine levels showed by the QM56-treated
group (Figure 7A). Moreover, QM56 also decreased tubular cell
DNA fragmentation and caspase-3 expression, both of them
indicative of cell apoptosis (Figure 7, B and C). Remarkably,
QM56-treated mice also displayed improved tubular damage
condition as was evaluated by a significantly lowered mRNA
synthesis of the early and sensitive AKI markers Kim-1 and Ngal
(Figure 7D). Mice treated with QM56 also shown a significantly
reduced renal inflammation as was evaluated by MCP-1 and
Rantes mRNA expression (Figure 8A) and decreased macrophage
and lymphocyte infiltration (Figure 8B). We also studied the
regulation of key proinflammatory signaling events we previously
showed to be targeted by QM56 in tubular cells (Figure 8C). The
mice AKI group displayed increased phospho JAK2 levels
compared to the control group. Accordingly, FA treated mice
exhibited both higher STAT3 and phosphorylated p65 nuclear
levels, accounting for previous phosphorylation-activation events
and p65 translocation, respectively. Furthermore, both JAK2/
STAT3 pathway activation and p65 phosphorylation were
significantly decreased in the QM56-treated mice group. Howev-
er, although QM56 did restrain NF-kB-dependent proinflamma-
tory gene synthesis, it did not avoid IkBa p65-dependent p65
nuclear translocation as was the case in cultured cells. Besides,
supporting this latter result, we also observed increased tubular
activation of p65 in folic acid induced AKI that was not affected
by QM56 treatment. Otherwise, folic acid-induced p65 phos-
phorylation was decreased by QM56 (Figure S4).
Discussion
The main finding of this study is that the QM56 nanoconjugate
has a previously non-described anti-inflammatory effect, indepen-
dent of cell death or Apaf-1, which may be mediated, at least in
part, by inhibition of JAK2 phosphorylation. In addition, we have
shown for the first time that QM56 protects cultured renal tubular
cells from apoptosis induced by nephrotoxins and inflammatory
cytokines. Thus, QM56 is a dual inhibitor of cell death and of
inflammation and these actions may underlie its protective effect
against AKI in vivo.
AKI is characterized by tubular cell death that is amplified by
an inflammatory response. Thus, an agent that directly inhibits cell
death and inflammation is a welcomed addition to the preclinical
drug pipeline for AKI. In this regard, in nephrotoxic AKI induced
by a folic acid overdose, a model that shares the main pathogenic
processes of cell death and proliferation, inflammation and fibrosis
with human AKI, results suggest that QM56 may improve renal
function and tissue injury evaluated by classical clinical parame-
ters, as well as through expression of more reliable biomarkers of
Nanoconjugate Prevents Inflammation in Renal Cells
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AKI such as Kim-1 and Ngal [2,26,27]. In this model, QM56
prevented the early occurrence of apoptotic cell death as well as
inflammation, the latter detected through lesser both chemokine
induction and immune cell infiltration in the kidney.
In vivo studies do not allow easy differentiation between direct
inhibition of inflammation, inhibition of cell death-generated
inflammation and inhibition of inflammation-generated cell death.
However, cell culture studies allow exploring the anti-inflamma-
Figure 3. QM56 prevents Tweak-induced NF-kB-dependent transcription, but not NF-kB p65/relA nuclear translocation or NF-kB
DNA-binding. A) Tweak-induced NF-kB transcriptional activity in MCT cells is inhibited by QM56. NF-kB transcriptional activity was expressed as a
percentage of Luciferase activity normalized to Renilla activity in a reporter gene assay. *p,0.01 vs Control; **p,0.05 vs Tweak (n = 3). B) Tweak
increases IkBa phosphorylation after 30 minutes of incubation and pretreatment with QM56 does not preclude this effect. Representative Western
blots are shown (n = 3). Protein bands in the sequence were arranged from non-consecutive lanes on the same membrane. C) QM56 does not
prevent NF-kB p65/relA nuclear translocation in response to Tweak. MCT cells were stimulated for 30 minutes with the stimuli alone or in the
presence of QM56 added 1 h before stimulation. Confocal microscopy: p65 (green), propidium iodide (red). Parthenolide was used as a control
inhibitor of p65 nuclear translocation. Arrows indicate individual cells shown nuclear localization of p65 NF-kB subunit. D) QM56 does not prevent
NF-kB DNA-binding activity in response to Tweak. Representative EMSA of nuclear extracts from MCT cells treated with Tweak alone or pretreated
with QM56.
doi:10.1371/journal.pone.0051992.g003
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Figure 4. Regulation of Tweak induction of chemokine mRNA by chemical inhibition of JAK2 kinase. A) Tweak promotes JAK2
phosphorylation in MCT cells which is prevented by the JAK2 inhibitor AG490 (AG). *p,0.05 vs Control; **p,0.05 vs Tweak (n = 3). B) Influence of
JAK2 (AG) inhibitor on Tweak-induced expression of MCP-1 and Rantes (*p,0.01 vs Control; ##p,0.01 vs Tweak) mRNA in MCT cells. Mean6SD of at
least three independent experiments. C) Inhibition of JAK2 with AG490 does not prevent Tweak-induced p65/RelA nuclear translocation. MCT cells
were stimulated for 30 minutes with the stimuli alone or in the presence of AG490 (AG) added 1 h before stimulation and then analyzed by confocal
microscopy. Arrows point to cells shown amplified as merge images in inset (p65 (green), propidium iodide (red)). D) Tweak-induced NF-kB
transcriptional activity is inhibited by JAK2 inhibition in MCT cells. NF-kB transcriptional activity was expressed as a percentage of Luciferase activity
normalized to Renilla activity in a reporter gene assay. *p,0.01 vs Control; **p,0.01 vs Tweak (n = 3). E) AG490 (AG) prevents the Tweak-stimulated
expression of MCP-1 and Rantes mRNA in MEF-Apaf-12/2 cells. *p,0.01 vs Control, **p,0.01 vs Tweak. Mean6SD of three independent experiments.
doi:10.1371/journal.pone.0051992.g004
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tory mechanisms of QM56 in addition to the anti-apoptotic
properties that had been previously characterized in non-renal
cells. QM56 protected from apoptosis induced either by exoge-
nous nephrotoxic agents, such as CsA, or by endogenous
inflammatory mediators that contribute to inflammation-induced
apoptosis in AKI, such as the cytokine combination Tweak/
TNFa/IFNc [6]. CsA is a key immunomodulatory drug whose use
in clinical transplantation is limited because of nephrotoxicity [28].
QM56 prevented both apoptosis and the expression of chemokine
mRNA induced by CsA or cytotoxic cytokines. The rapid
inhibitory action of QM56 on the inflammatory response elicited
by CsA or Tweak/TNFa/INFc strongly suggested this effect was
not attributable to distal inhibition of apoptosis through Apaf-1
binding. To unravel whether the limitation of the inflammatory
response by QM56 was related to its cytoprotective effect, we
focused our studies on Tweak. Tweak is a TNF superfamily
cytokine that, by itself, in the absence of additional mediators of
inflammation, does not promote tubular cell apoptosis [6], as
confirmed in this manuscript. QM56 also inhibited the inflam-
matory response induced by this non-cytotoxic cytokine. Indeed,
inhibition of chemokine mRNA expression was observed as early
as 30 minutes following addition of Tweak, suggesting a direct
anti-inflammatory action of QM56. Since NF-kB is a key
transcription factor in inflammation and had been shown to
mediate Tweak-induced transcription of chemokine mRNA in
tubular cells [2,4], we explored whether QM56 interfered with
NF-kB activation. Both MCP-1 and Rantes are canonical p65/
RelA targets [29]. QM56 prevented transcriptional activation by
NF-kB but we could not demonstrate inhibition of p65/RelA
translocation to the nucleus or generation of DNA-binding NF-kB
complexes. Interestingly, cells treated with AG490, displayed a
similar pattern of inhibition of Tweak-induced, NF-kB-dependent
Figure 5. QM56 inhibits Tweak-dependent JAK2/STAT-3 pathway activation. MCT (A and B) and MEF-Apaf-12/2 (C) cells were treated with
100 ng/ml Tweak, alone or pretreated with QM56 (20 mmol/L) for 1 h before Tweak addition. JAK2 and STAT-3 phosphorylation were evaluated by
Western blot in cells stimulated with Tweak for the indicated times. Phosphorylated STAT-3 was also evaluated by confocal microscopy 40 min.
following Tweak stimulation. The figures are representative of three independent experiments. A) QM56 prevents Tweak-induced JAK2 activation
and the downstream STAT-3 phosphorylation. Bands in the sequence were arranged from non-consecutive lanes on the same membrane. *p,0.05 vs
Control; #p,0.05 vs Tweak (n = 3). B) QM56 also prevents the STAT-3 (green) nuclear translocation elicited by Tweak. Arrows indicate representative
nuclei of each culture condition that are shown in detail in a merged green-propidium iodide image inset in each treatment photograph. C) QM56
hinders Tweak-induced JAK2/STAT3 phosphorylation in cells lacking Apaf-1 (MEF-Apaf-12/2).*p,0.05 vs Control; #p,0.05 vs Tweak (n = 3).
doi:10.1371/journal.pone.0051992.g005
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transcription of chemokine-encoding genes and of a reporter gene
assay, without inhibition of RelA translocation to the nucleus.
AG490 is a tyrphostin JAK2 inhibitor [30], so we explored in
depth the influence of QM56 on JAK2 activation.
Active JAK2 promotes phosphorylation and activation of the
STAT family of transcription factors [31]. The JAK2/STAT3
pathway has been linked to generation of inflammation [32–38].
Although Tweak activation of JAK2 had not been reported
previously, another TNF superfamily receptor, TNFR1, associates
with JAK2 and TNFR1/JAK2 activates downstream kinases [37].
JAK2 may promote MCP-1 transcription and JAK2 targeting
impaired the induction of MCP-1 by TNFa or IL-6 [33,35,36,38].
RANTES may also be regulated by JAK2 signaling [34]. Recent
evidence suggests the existence of connecting points between NF-
kB and JAK/STAT signaling pathways [34,37]. Both NF-kB and
JAK2/STAT3 signaling is required for induction of MCP-1 or
Rantes mRNA expression induced by Cardiotrophin-1 in
HUVEC or gangliosides in brain microglial cells [34,37,39,40].
Here, we demonstrated for the first time that Tweak activates
JAK2 and STAT3 at very early time points and that QM56
prevents this activation, consistently with the early effect of QM56
on chemokine expression.
Kinases may phosphorylate regulatory proteins upstream of NF-
kB as well as NF-kB itself and modulate NF-kB function [23]. We
have now identified a Tweak-dependent JAK2 activity required
for NF-kB phosphorylation at Ser536 and for NF-kB-dependent
MCP-1 and Rantes transcription. Phosphorylation of Ser536 is
independent from IkBa activity and steers the transcription of a set
of inflammatory genes without affecting nuclear translocation,
DNA binding of p65 or the general activation of NF-kB [24]. Both
AG490 and QM56 prevented Tweak-induced NF-kB p65
phosphorylation at Ser536. This may explain QM56 prevention
of Tweak-induced upregulation of NF-kB-dependent chemokine
mRNA expression in the absence of changes in nuclear
translocation of NF-kB p65 and NF-kB DNA binding. Supporting
the hypothesis that only certain p65-dependent genes would be
regulated by p65 phosphorylation at Ser536, QM56 or AG490
failed to prevent TWEAK-induced, NF-kB p65-dependent Klotho
mRNA downregulation (unpublished observation) [41]. Further-
more, we additionally proved that QM56 also prevented LPS
agonistic activity on NF-kB and inflammation by inhibiting the
JAK2/STAT3 pathway and p65 phosphorylation, so confirming
that the anti-inflammatory effect of QM56 is stimulus-independent
and restricted to the JAK2-dependent signaling pathway. More-
over, the JAK2/STAT3 and NF-kB/p-p65 proinflammatory
pathways were revealed to be active in kidneys from mice treated
with folic acid and further repressed by QM56.
QM56 was originally described as an Apaf-1 CARD binding
chemical inhibitor [10,11]. However QM56 inhibited JAK2 and
STAT-3 phosphorylation and chemokine mRNA expression in
response to Tweak in Apaf-1 null cells, suggesting additional
targets for the anti-inflammatory action of QM56. QM56 is a
polymeric compound that integrates the first generation of Apaf-1
inhibitors directly derived from a library screening [11]. The
CARD domain is a protein-binding motif that interacts with
Figure 6. QM56 and JAK2 inhibition negatively regulate
Tweak-induced p65 phosphorylation. A) Tweak phosphorylates
p65. MCT cells were treated with 100 ng/ml Tweak for the indicated
times and phosphorylation of p65 in the Ser536 analyzed by Western
blot. Representative figure of three individual experiments. B) QM56
and JAK2 inhibition prevent p65 phosphorylation. MCT cells were
treated with 100 ng/ml Tweak for 3 h in the absence or in the presence
of QM56 or AG490 (AG) added 1 h before the cytokine. Phosphorylated
p65 was analyzed by Western blot. The figure shows a representative
experiment and quantitation as Mean6SD of five independent
experiments (*p,0.01 vs Control, **p,0.05 vs Tweak). C) QM56 and
AG490 (AG) inhibit p65(Ser536) phosphorylation and nuclear translo-
cation. MCT cells were treated as in B. Phospho-p65(Ser536) was
studied by confocal microscopy. Arrows indicate representative cells
with nuclear location of phospho-p65(Ser536) which are shown in detail
in a merged green-propidium iodide image inset.
doi:10.1371/journal.pone.0051992.g006
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Figure 7. QM56 reduces the degree of renal disfunction and damage in acute kidney injury. AKI was induced by a single folic acid (FA)
overdose and mice were killed at 24 h. QM56 decreased the magnitude of renal failure as assessed by: plasma urea and creatinine (*p,0.01 vs
Control, **p,0.05 vs FA) (A), tubular cell apoptosis as assessed by TUNELH (*p,0.01 vs Control, **p,0.05 vs FA) and immunohistochemistry of
caspase-3 (*p,0.01 vs Control, **p,0.02 vs FA) (B,C) and Kim-1 and Ngal mRNA hindered synthesis (*p,0.01 vs Control, #p,0.01 vs FA, **p,0.05 vs
FA) (D). In C, black arrows indicate caspase-3 positive tubuli. Control for the technique (negative control, NC) is stained in the absence of primary
antibody. Magnifications:6200. Mean6SD of 8–10 mice per group.
doi:10.1371/journal.pone.0051992.g007
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Figure 8. QM56 reduces renal inflammation in acute kidney injury. AKI was induced by a single folic acid (FA) overdose and mice were
killed at 24 h. A) renal expression of MCP-1 and Rantes as assessed by qRT-PCR (*p,0.05 vs Control, **p,0.05 vs FA). B) The increased number of
interstitial macrophage stained with anti CD68 (left panel) or CD3 (right panel) in AKI kidneys was reduced by QM56. Representative images of groups of
mice control (a) treated with FA (c and detail in e) and treated with FA and QM56 (d and detail in f). Controls for the technique were stained in the
absence of primary antibodies (b). Arrows on c, d, e and f indicate macrophage infiltration (left panel) and lymphocyte infiltration (right panel). Delimited
area in c and d are correspondingly amplified in e and f, respectively. Original magnifications6200 and details6400. Quantification as Means6SD of 5
mice per group (*p,0.02 vs Control, **p,0.02 vs FA, #p,0.01 vs Control, ##p,0.01 vs FA) C) Western blots of nuclear (N) and cytoplasmatic (C) mouse
kidney extracts from representative untreated control and FA and FA+QM56-treated mice. The phosphorylated form of JAK2 is increased in the folic acid-
induced AKI group (1.460.1 fold increase vs Control group, p,0.02) and reduced by treatment with QM56 (1.1.60.1 fold increase vs Control group,
p,0.01 vs FA group). JAK2 activation induces both STAT3 nuclear translocation and phosphorylation of p65 in nuclei and they were prevented by QM56.
However, IkBa phosphorylation and p65 nuclear translocation were not affected by QM56.
doi:10.1371/journal.pone.0051992.g008
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caspases through CARD-CARD interactions. CARD domains
have been found in many adaptor proteins not related to apoptosis
that mediate inflammatory responses and may regulate NF-kB
signaling [42]. However, the modulation of additional intracellular
inflammation signaling pathways by CARD-containing proteins
has been less characterized. The CARD containing NLRP1
protein has a crucial role in the activation of pro-inflammatory
caspases through the formation of the inflammasome but also
modulates Apaf-1 function through CARD/CARD interactions
[43,44], suggesting the presence of a crosstalk between pathways.
At present it is not known whether a molecule that binds to Apaf-1
CARD could have some residual affinity to bind CARD domains
of other protein families, including those relevant for inflammatory
processes. Improved generations of Apaf-1 inhibitors with
restricted chemical conformations that would improve specific
CARD-domain selectivity are being developed. In the same
manner, QM56 offers an interesting platform to further develop
inflammation targeting inhibitors.
In conclusion, the QM56 nanoconjugate has a novel, apoptosis-
independent, anti-inflammatory action that appears at least in part
related to JAK2 inhibition and results in inhibition of transcrip-
tional regulation of certain NF-kB proinflammatory targets. The
combination of both the antiapoptotic and the anti-inflammatory
effect may be beneficial in AKI. Additional studies are needed to
further characterize the molecular and structural basis of the anti-
inflammatory action and to develop novel therapeutic compounds.
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Figure S1 Apaf-1 expression in murine embryonic
fibroblasts (MEF) derived from Apaf-1 knock out mice
and wild-type controls. Apaf-1 gene (A) and protein expression
(B) levels in MEF-Apaf-1+/+ and MEF-Apaf-12/2 evaluated by
PCR and Western blot, respectively.
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Figure S2 QM56 inhibits CsA and Tweak/TNFa/INFc-
induced JAK2 activation. JAK2 is activated by 10 mg/ml CsA
or 100 ng/ml Tweak, 30 ng/ml TNFa, 30 U/ml IFNc in MCT
cells and QM56 prevented this effect. Representative Western blot
of three independent experiments.
(TIFF)
Figure S3 QM56 inhibits LPS-induced NF-kB activation
and NF-kB proinflammatory activity. MCP1 and Rantes
mRNA (qRT-PCR) synthesis (A) and JAK2, Stat3 and phospho(-
Ser536)-p65 pathway (B) were activated by 1 mg/ml LPS added to
MCT cells at the specified times and down-regulated by QM56
pretreatment. In A, results are expressed as the Mean6SD of
three independent experiments. *p,0.01 vs Control, **p,0.05
and #p,0.02 vs LPS. In B, figures are representative of three
independent experiments. Protein bands in the sequence were
arranged from non-consecutive lanes on the same membrane.
(TIFF)
Figure S4 QM56 treatment in folic acid-induced AKI
reduces the nuclear localization of phospho(Ser536)-p65
in renal tubules. In AKI group, tubules with an increased
nuclear expression of p65 (asterisk) also present an increased
nuclear expression of phospho-p65 (Ser536), but not in kidney
tubules from the QM56 treated group. p65 and phospho-p65
(Ser536) are detected by immunohystochemical staining in the
same renal tubules. Original magnification6200.
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